James L. Gulley

Genitourinary Malignancies Branch
The Center for Cancer Research
United States of America

Scientist Immunology
Biography

Dr. James Gulley is an internationally recognized expert in immunotherapy for cancer. He graduated from Loma Linda University in California with a Ph.D. in microbiology in 1994 and an M.D. in 1995. As part of this eight-year M.D./Ph.D. Medical Scientist Training Program he completed a dissertation on tumor immunology. Dr. Gulley completed his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI. Since 1999 he has authored and run a variety of clinical trials at the NCI, serving as Principal Investigator or Associate Investigator on more than 60 trials. Dr. Gulley has received numerous awards, including the 2010 Presidential Early Career Award for Scientists and Engineers (PECASE), the highest award bestowed by the U.S. government on outstanding scientists early in their careers. He serves on many national and NIH boards and committees. Dr. Gulley has authored more than 180 scientific papers and book chapters, edited 4 books and has made numerous invited presentations at national and international meetings. 

Research Intrest

Clinical Research, Immunology 

List of Publications
Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, et al. (2013) Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol. Immunother. 62: 1521-1531.
Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, et al. (2012) Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13: 501-508.
Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, et al. (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother 59: 663-674.
Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, et al. (2010) Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28: 1099-1105.
Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, et al. (2007) Clinical safety of a viral vector based prostate cancer vaccine strategy. J. Urol. 178: 1515-1520.